Blueprint Medicines
BPMC
BPMC was delisted on the 17th of July, 2025.
220 hedge funds and large institutions have $3.25B invested in Blueprint Medicines in 2023 Q3 according to their latest regulatory filings, with 27 funds opening new positions, 98 increasing their positions, 55 reducing their positions, and 26 closing their positions.
78% more repeat investments, than reductions
Existing positions increased: 98 | Existing positions reduced: 55
1.1% more ownership
Funds ownership: 105.59% → 106.69% (+1.1%)
4% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 26
1% less funds holding
Funds holding: 222 → 220 (-2)
19% less capital invested
Capital invested by funds: $4.03B → $3.25B (-$780M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
67% less call options, than puts
Call options by funds: $13.3M | Put options by funds: $40.4M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$33.3M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$31.8M |
| 3 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$28.9M |
| 4 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$26.6M |
| 5 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$18M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$114M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$33.3M |
| 3 |
Fisher Asset Management
Camas,
Washington
|
-$22.3M |
| 4 |
CC
Casdin Capital
New York
|
-$13.3M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$6.78M |
BPMC Hedge Fund Activity: Q3 2023 in Review
220 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Blueprint Medicines (BPMC) for Q3 2023, worth a combined $3.25B — down 19% from $4.03B a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new BPMC positions and 26 closed out — a net gain of 1 holder — while 98 added to existing stakes and 55 trimmed.
The largest buyer was Millennium Management, adding an estimated $33.3M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $114M sold.
- 220 institutional investors held Blueprint Medicines (BPMC) as of Q3 2023, down from 222 in Q2 2023.
- Funds reported $3.25B of Blueprint Medicines stock for Q3 2023, down 19% quarter-over-quarter.
- 27 funds opened new Blueprint Medicines positions in Q3 2023 and 26 closed out, a net change of +1 holder.
- The largest Blueprint Medicines buyer in Q3 2023 was Millennium Management, an estimated $33.3M added.
- The largest Blueprint Medicines seller in Q3 2023 was EcoR1 Capital, an estimated $114M sold.
Based on aggregated 13F filings for Q3 2023.